Regeneron has partnered with The Foundation Fighting Blindness to raise awareness about an ongoing clinical trial investigating subcutaneously administered investigational medicines as potential treatments for geographic atrophy (GA). The study will evaluate two approaches: an investigational combination therapy and an investigational single therapy, both administered under the skin rather than through injections into the eye.
The primary goal of this trial is to assess safety and efficacy—specifically whether these investigational medicines may help slow the progression of GA and prevent further vision loss.
Participants will be randomly chosen to receive either the investigational combination therapy, investigational monotherapy, or placebo. Participants will receive subcutaneous injections at regular intervals, with the potential to treat both eyes without intravitreal injections. After the initial dose, all participants will be monitored and dosed at regular intervals for two years, with an option to continue for an additional three years. Reasonable travel expenses for required visits may be reimbursed, and all trial-related services are provided at no cost.
The trial is called:
“A Study Investigating Subcutaneously Administered Combination Therapy or Monotherapy in Adult Participants With Geographic Atrophy (SIENNA).”
Please note: This clinical trial involves investigational drug products whose safety and efficacy have not been fully evaluated by regulatory authorities, and which have not received marketing authorization in any country
VV-CRC-003012